Santhera Pharmaceuticals has announced that results from the RHODOS study evaluating the efficacy of Catena® in Leber Hereditary Optic Neuropathy (LHON) will be presented at the 21st Meeting of the European Neurological Society in Lisbon, Portugal.
The presentation entitled A Randomized, Placebo-Controlled Trial of Idebenone in Leber's Hereditary Optic Neuropathy will be given on May 30, 2011 at 16:00 CET.
Data will be presented by the co-principal investigator, Professor Thomas Klopstock from the Friedrich-Baur-Institut at the Department of Neurology, University of Munich, Germany.
The results from the RHODOS study show that Catena® can protect the vision of patients, who are at highest risk of vision loss, and enhance the recovery of visual acuity in severely affected patients.
These data are supported by secondary, clinically meaningful efficacy variables such as color contrast sensitivity, changes in retinal nerve fiber layer thickness and clinical benefit.
In the study, Catena® showed consistent clinically relevant superiority over placebo. Santhera will file a Marketing Authorization Application with the European Medicines Agency in the first half of 2011.